Dr. William Horan (Bristol Myers Squibb) joins AJP Audio to discuss a newly approved, novel treatment for schizophrenia spectrum disorder, which has potential impacts for cognition in patients. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin puts the rest of the March issue into context.

00:45 Horan interview
03:15 Novel mechanism of action in the treatment of schizophrenia
05:39 Side effect profiles
07:20 Clinical impacts
08:31 The need for further investigation
09:58 Limitations
11:05 Further research
13:08 Kalin interview
13:21 Horan et al.
17:34 Levenstein et al.
19:00 Fountoulakis et al.
20:57 Couture et al.
23:18 Stern et al.
27:35 McGirr et al.

Transcript

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org

March 2025: The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials